ENDONOVO THERAPEUTICS, INC. (ENDV)
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Biotechnology
Endonovo Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 318.75M shares outstanding
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications.
The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
Leadership
Alan Brian Collier
Chairman & Chief Executive Officer
Don Calabria
Vice President of Operations
Garry Michael Kann
Head of Corporate Development
Ira Weisberg
President & Chief Commercial Officer of Medical Division
Employees
1
Country
US
Sector
Healthcare
Website
endonovo.com
based on 318.75M shares outstanding
30d Avg
225.47K
60d Avg
521.41K
90d Avg
727.28K